SANUWAVE Health, Inc.
About SANUWAVE Health, Inc.
SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $44.1M
- Net income
- $11.8M
- Total assets
- $37.3M
- Market cap
- $126.9M
- Gross margin
- 77.1%
- Operating margin
- 11.2%
- Net margin
- 26.8%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $44.1M
- Cost of revenue
- $10.1M
- Gross profit
- $34.0M
- Operating expenses
- $29.0M
- Operating income
- $4.9M
- Income tax
- $86.0K
- Net income
- $11.8M
- EPS (basic)
- $1.38
- EPS (diluted)
- $0.41
Balance sheet
- Total assets
- $37.3M
- Current assets
- $24.6M
- Total liabilities
- $35.7M
- Current liabilities
- $17.8M
- Shareholders’ equity
- $1.6M
Cash flow
- Operating cash flow
- $3.9M
- Investing cash flow
- $3.4M
- Financing cash flow
- -$5.6M
- Net cash flow
- $1.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $126.9M
- P/E ratio
- 35.5
- EPS (diluted)
- $0.41
- Shares outstanding
- 8.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 8, 2008
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $11.8M in FY2025.
- Gross margin of 77.1%, net margin 26.8%.
- Trading 68% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 35.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SANUWAVE Health, Inc..
Write a review
News about SANUWAVE Health, Inc.
News & sentiment via Polygon.io
